Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal

Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.